The Clinical Efficacy and Safety of Iguratimod in RA and Early RA Patients for 6 Months Treatment
Status:
Active, not recruiting
Trial end date:
2021-12-11
Target enrollment:
Participant gender:
Summary
This study is designed to observed prospectively the efficacy and safety of 6 months
treatment of iguratimod alone, or with methotrexate (MTX), hydroxychloroquine (HCQ) and
prednisone step by step on Chinese rheumatoid arthritis (RA) and early rheumatoid arthritis
(ERA) patients who were naïve or shown insufficiency response or intolerance to DMARDs. If
volunteered, patients who completed the 6-month study can continue to follow our plans for 24
months.